Cobbery vs Isomorphic Labs

Side-by-side comparison of features, pricing, and ratings

Analysis reviewed Live tool data as of 2026-08-23
Cross-checked through our multi-step verification ·
Saved

At a glance

DimensionCobberyIsomorphic Labs
PricingContact for pricingContact for pricing
Target UsersHigh-stakes litigation teamsPharma companies for drug discovery partnerships
Core TechnologyAI agent 'Gene' for litigation case strategyAlphaFold-based Drug Design Engine
Deployment ModelAir-gapped, per-matter isolated infrastructurePartnership-based, custom for each pharma collaboration
Funding/BackingNot disclosed$600M external investment (2025), Series B (Feb 2026)
Best ForLitigators in 9-figure or complex scientific casesLarge-scale drug development programs

Cobbery and Isomorphic Labs serve entirely different domains—law and drug discovery—so the choice depends on your field. For high-stakes litigation teams needing an AI agent that streamlines case strategy and fact analysis, Cobbery is purpose-built. Isomorphic Labs is for pharma companies seeking AI-driven drug design, but only through deep partnerships. If you're not in pharma or large-scale litigation, neither is a fit.

Cobbery
Cobbery

Litigation AI agent that gives trial teams superpowers in high-stakes cases.

Visit Website
Isomorphic Labs
Isomorphic Labs

AI-first drug discovery partner built on Nobel-winning AlphaFold.

Visit Website
Pricing
Contact Sales
Contact Sales
Plans
Popularity
2 views
7.4k views
Skill Level
Advanced
Advanced
API Available
Platforms
Web
Categories
⚖️ Contracts, E-Signature & Legal
🧬 Drug Discovery & Life Sciences
Features
Gene AI agent collaborates on trial themes and case strategy
Single source of truth for case record, production, facts, and strategy
Proactively flags facts that strengthen or weaken trial themes
Identifies appellate issues early in the case
Predicts opposing counsel moves
Agents test hypotheses before expert hours are billed
Experts review finished AI findings to verify credibility
Rapid onboarding of new counsel to case knowledge
Reads new filings instantly and flags contradictions
Generates deposition and cross-examination outlines
Intuitive email inbox integration
Air-gapped AI agents (no arbitrary internet communication)
SOC 2 compliance for audited security
Cobbery cannot see user files or conversations
Isolated infrastructure per matter for risk reduction
Built on Nobel-winning AlphaFold system
Generative AI molecule design via Drug Design Engine
Predictive AI models for protein-ligand interactions
Digital biology simulation at scale
End-to-end drug discovery from target ID to lead optimization
Partnership model with Novartis and Johnson & Johnson
Drug metabolism and toxicity simulation
Bioresilience framework for pandemic preparedness
US operations established in 2025
Series B funding in February 2026
Max Jaderberg appointed as President
Dr. Ben Wolf appointed as Chief Medical Officer
Interdisciplinary team of ML and drug discovery experts
Integrations
Email inbox

What real users say: Cobbery vs Isomorphic Labs

Not marketing copy and not our opinion — a structured sweep of public discussion (reviews, forums, communities and video comments), showing what people praise and what they complain about for each tool.

Cobbery

2 mentions across 2 sources · 0% positive — critical

Hacker News, Product Hunt

What users praise

  • Air-gapped AI and SOC 2 compliance for sensitive litigation data.
  • Single source of truth for case facts, record, and strategy.
  • Proactive flagging of facts that strengthen or weaken trial themes.
  • Hypothesis testing before billing expert hours, saving costs.

What frustrates them

  • Absolutely no verified user feedback from any community platform.
  • Pricing is hidden behind contact sales, potentially high.
  • No publicly known integrations beyond email inbox.
  • Learning curve unknown for non-technical legal teams.

Researched Jul 3, 2026

Isomorphic Labs

48 mentions across 3 sources · 82% positive

Hacker News, YouTube, Lemmy

What users praise

  • Built on the Nobel-winning AlphaFold, giving it instant credibility in structural biology.
  • Drug Design Engine extends beyond structure to generative molecule design, promising novel chemistry.
  • Deep partnerships with Novartis and J&J, with potential billions in royalties.
  • Interdisciplinary team of top ML and drug discovery experts, ensuring depth of expertise.

What frustrates them

  • Not accessible to individual researchers or small biotech due to partnership model only.
  • Proprietary nature of parts of its tech limits community scrutiny and independent validation.
  • CASP16 results suggest AlphaFold 3-based models aren't always better than older methods for protein-ligand interactions.
  • No marketed drugs yet; outcomes remain uncertain with royalties tied to long timelines.

Researched Aug 18, 2026

Who should pick which

  • Litigation team handling a 9-figure patent case
    Pick: Cobbery

    Cobbery's AI agent Gene helps build trial themes, analyze facts, predict opposing counsel, and generate deposition outlines—all in a secure, air-gapped environment tailored for complex litigation.

  • Pharma company developing a new oncology drug
    Pick: Isomorphic Labs

    Isomorphic Labs offers a Drug Design Engine built on AlphaFold for AI-driven lead optimization and novel molecule design, backed by deep partnerships and strong funding.

  • Solo practitioner handling small-scale litigation
    Pick: Cobbery

    Cobbery is not for solo practitioners; it's designed for large teams in high-stakes cases. Solo practitioners should look for more affordable litigation tools.

  • Individual researcher exploring drug repurposing
    Pick: Isomorphic Labs

    Isomorphic Labs only works through pharma partnerships; it's not a tool for independent researchers. Consider open-source alternatives like AlphaFold or other accessible AI models.

Frequently Asked Questions

Cobbery vs Isomorphic Labs: which should you choose?

Cobbery and Isomorphic Labs serve entirely different domains—law and drug discovery—so the choice depends on your field. For high-stakes litigation teams needing an AI agent that streamlines case strategy and fact analysis, Cobbery is purpose-built. Isomorphic Labs is for pharma companies seeking AI-driven drug design, but only through deep partnerships. If you're not in pharma or large-scale litigation, neither is a fit.

What is the core difference between Cobbery and Isomorphic Labs?

Cobbery is an AI agent for litigation case strategy and fact analysis, while Isomorphic Labs is an AI-powered drug discovery platform for pharma companies. They serve completely different industries.

Can I use Cobbery for transactional legal work?

No. Cobbery is purpose-built for litigation, not transactional, corporate, or other non-litigation legal work.

Is Isomorphic Labs available as a software product or API?

No. Isomorphic Labs operates only through deep pharma partnerships, not as a standalone product or API for individual researchers.

Does Cobbery integrate with common legal tools?

Cobbery integrates with email inboxes, but its integration list is limited. It is designed to work as a standalone single source of truth.

Isomorphic Labs raised $600M—does that affect pricing?

Pricing remains contact-based, likely high for multi-year partnerships. The funding indicates long-term commitment, not lower cost.

Which tool is more secure?

Cobbery emphasizes air-gapped, SOC 2 compliant, per-matter isolated infrastructure. Isomorphic Labs likely maintains security but has not publicly detailed it.

Can a small law firm use Cobbery?

Cobbery is best for high-stakes litigation; small firms with low-volume cases may find it too expensive or overkill.

Isomorphic Labs partnership with Johnson & Johnson—what does it mean?

This collaboration (announced Jan 2026) reinforces Isomorphic Labs' focus on large-scale pharma partnerships, not general availability.

More Cobbery or Isomorphic Labs comparisons

Explore each tool further

Browse these categories

Still deciding? Get the weekly AI tools brief

One email a week — new tools, honest comparisons, no spam.

Last reviewed: July 3, 2026